ESTA

Establishment Labs is leveraging FDA approval and U.S. market entry to drive higher-margin growth through procedure-based offerings like Preservé. Q2 2026 results showed 31.7% revenue growth, gross margin expansion to 70.6%, and U.S. sales accounting for 89% of total growth. Preservé delivers over 2x revenue per procedure versus traditional augmentation, but long-term success hinges on repeat utilization and durable economics.

Establishment Labs NASDAQ: ESTA reported second-quarter revenue growth of 31.7% year over year, driven by continued rapid expansion in the United States, rising adoption of its Minimally Invasive platform and improving operating leverage.

Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.57 per share a year ago.

NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2026, before the market opens on Thursday, August 6, 2026, and will host a conference call at 8:30 AM ET that day to discuss those results. To participate in the conference call, Dial: (+1) 888-396-8049 (US &amp.

JW Asset Management sold 90,533 shares between May 26 and May 28, 2026, generating a transaction value of ~$6.64 million at a weighted average price of around $73.31 per share. The transaction represented 3.04% of the insider's total indirect holdings, reducing indirect ownership from ~2.98 million to ~2.89 million shares.

NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Taylor Harris to its Board of Directors. Mr. Harris brings more than 25 years of experience in corporate finance, executive leadership and board governance across healthcare, medical technology and life sciences companies. He currently serves on t.

NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, will be added as a member of the US small-cap Russell 2000® Index, effective when the US market opens on June 29th as part of the 2026 Russell indexes reconstitution. Membership in the Russell 2000® Index, which remains in place for half a year beginning 2026, is based on membershi.

WEST JORDAN, Utah, May 18, 2026 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the appointment of Raj Denhoy to the role of Chief Financial Officer (CFO) effective today. “Route 92 Medical has built a strong position in neurovascular intervention,” said Raj Denhoy, CFO at Route 92 Medical.

Establishment Labs Holdings Inc. (ESTA) Q1 2026 Earnings Call Transcript

Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.7 per share a year ago.